Phaseline

Companies › Cellectis

Cellectis: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
UCART20x22
Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptor
CD20, CD22Phase 1B-cell Non-Hodgkin Lymphoma (B-NHL)Aug 2027
UCART123v1.2
Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor
CD123Phase 1Relapsed/Refractory Acute Myeloid Leukemia–
UCART22
Allogeneic engineered T-cells expressing anti-CD22 chimeric antigen receptor (CAR-T)
CD22Phase 1B-cell Acute Lymphoblastic Leukemia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03190278UCART123v1.2Phase 1Relapsed/Refractory Acute Myeloid LeukemiaOncologyDec 2024
NCT04150497UCART22Phase 1B-cell Acute Lymphoblastic LeukemiaOncologyJun 2026
NCT05607420UCART20x22Phase 1B-cell Non-Hodgkin Lymphoma (B-NHL)OncologyAug 2027

From the company's SEC filings

Cash of $62m on 2025-12-31; operating cash outflow about $40m a year; runway about 19 months at that burn, to Jul 2027

Targets

CD22 (2) CD123 (1) CD20 (1)

Companies with the same targets

AstraZeneca Hebei Senlang Biotechnology Gilead Sciences Pfizer Umoja Biopharma Chongqing Precision Biotech AvenCell Europe MacroGenics Johnson & Johnson (Janssen) Shanghai Jiaolian Drug Research and Development

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.